×
S&P 500   3,802.97 (-0.49%)
DOW   30,923.97 (-0.07%)
QQQ   283.00 (-0.19%)
AAPL   139.42 (+1.44%)
MSFT   259.53 (+1.19%)
META   163.69 (+1.87%)
GOOGL   2,228.92 (-0.50%)
AMZN   108.98 (+1.47%)
TSLA   671.00 (-3.87%)
NVDA   154.10 (-3.58%)
NIO   21.44 (-4.11%)
BABA   115.72 (-0.89%)
AMD   76.71 (-5.04%)
MU   55.70 (-3.73%)
CGC   3.52 (-2.49%)
T   20.80 (+0.92%)
GE   64.01 (-2.84%)
F   11.47 (-2.88%)
DIS   95.25 (-0.70%)
AMC   13.36 (-0.15%)
PFE   51.12 (+0.91%)
PYPL   71.18 (-0.89%)
NFLX   176.72 (-1.60%)
S&P 500   3,802.97 (-0.49%)
DOW   30,923.97 (-0.07%)
QQQ   283.00 (-0.19%)
AAPL   139.42 (+1.44%)
MSFT   259.53 (+1.19%)
META   163.69 (+1.87%)
GOOGL   2,228.92 (-0.50%)
AMZN   108.98 (+1.47%)
TSLA   671.00 (-3.87%)
NVDA   154.10 (-3.58%)
NIO   21.44 (-4.11%)
BABA   115.72 (-0.89%)
AMD   76.71 (-5.04%)
MU   55.70 (-3.73%)
CGC   3.52 (-2.49%)
T   20.80 (+0.92%)
GE   64.01 (-2.84%)
F   11.47 (-2.88%)
DIS   95.25 (-0.70%)
AMC   13.36 (-0.15%)
PFE   51.12 (+0.91%)
PYPL   71.18 (-0.89%)
NFLX   176.72 (-1.60%)
S&P 500   3,802.97 (-0.49%)
DOW   30,923.97 (-0.07%)
QQQ   283.00 (-0.19%)
AAPL   139.42 (+1.44%)
MSFT   259.53 (+1.19%)
META   163.69 (+1.87%)
GOOGL   2,228.92 (-0.50%)
AMZN   108.98 (+1.47%)
TSLA   671.00 (-3.87%)
NVDA   154.10 (-3.58%)
NIO   21.44 (-4.11%)
BABA   115.72 (-0.89%)
AMD   76.71 (-5.04%)
MU   55.70 (-3.73%)
CGC   3.52 (-2.49%)
T   20.80 (+0.92%)
GE   64.01 (-2.84%)
F   11.47 (-2.88%)
DIS   95.25 (-0.70%)
AMC   13.36 (-0.15%)
PFE   51.12 (+0.91%)
PYPL   71.18 (-0.89%)
NFLX   176.72 (-1.60%)
S&P 500   3,802.97 (-0.49%)
DOW   30,923.97 (-0.07%)
QQQ   283.00 (-0.19%)
AAPL   139.42 (+1.44%)
MSFT   259.53 (+1.19%)
META   163.69 (+1.87%)
GOOGL   2,228.92 (-0.50%)
AMZN   108.98 (+1.47%)
TSLA   671.00 (-3.87%)
NVDA   154.10 (-3.58%)
NIO   21.44 (-4.11%)
BABA   115.72 (-0.89%)
AMD   76.71 (-5.04%)
MU   55.70 (-3.73%)
CGC   3.52 (-2.49%)
T   20.80 (+0.92%)
GE   64.01 (-2.84%)
F   11.47 (-2.88%)
DIS   95.25 (-0.70%)
AMC   13.36 (-0.15%)
PFE   51.12 (+0.91%)
PYPL   71.18 (-0.89%)
NFLX   176.72 (-1.60%)
NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$13.75
0.00 (0.00%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.75
$13.75
50-Day Range
$10.05
$14.39
52-Week Range
$9.93
$34.30
Volume
164 shs
Average Volume
960 shs
Market Capitalization
$639.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock Forecast (MarketRank)

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1262nd out of 1,433 stocks

Pharmaceutical Preparations Industry

621st out of 685 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Zealand Pharma A/S logo

About Zealand Pharma A/S (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

ZEAL Stock News Headlines

Dr. David Kendall named Zealand Pharma CMO
Why Zealand Pharma Shares Are Rising
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZEAL
Employees
355
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/29/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-161.99 million
Net Margins
-380.22%
Pretax Margin
-364.34%

Debt

Sales & Book Value

Annual Sales
$46.54 million
Book Value
$3.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$639.79 million
Optionable
Not Optionable
Beta
1.37














Zealand Pharma A/S Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S
or view top-rated stocks.

How has Zealand Pharma A/S's stock price performed in 2022?

Zealand Pharma A/S's stock was trading at $21.34 at the beginning of 2022. Since then, ZEAL stock has decreased by 35.6% and is now trading at $13.75.
View the best growth stocks for 2022 here
.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Zealand Pharma A/S
.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Thursday, May, 12th. The company reported ($5.16) EPS for the quarter, topping the consensus estimate of ($6.61) by $1.45. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 89.90% and a negative net margin of 380.22%. During the same period in the previous year, the firm earned ($0.94) earnings per share.
View Zealand Pharma A/S's earnings history
.

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Mr. Adam Sinding Steensberg M.D., Pres & CEO (Age 48, Pay $729.62k)
  • Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 47, Pay $587.7k)
  • Mr. Ivan Mourits Moller, Chief Operating Officer (Age 50)
  • Lani Pollworth Morvan, Investor Relations & Communications Officer
  • Mr. Mads Kronborg, Head of Investor Relations & Communication
  • Mr. Ravinder Chahil, Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal, Sr. VP and Global Head of People & Organization (Age 37)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 69)
  • Dr. Jens Damsgaard Mikkelsen M.D., Head of Molecular Pharmacology
  • Dr. Danilo Verge, Head of Global Medical Affairs

What other stocks do shareholders of Zealand Pharma A/S own?

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are Zealand Pharma A/S's major shareholders?

Zealand Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (1.14%) and Bank of America Corp DE (0.51%).

Which major investors are selling Zealand Pharma A/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC.

Which major investors are buying Zealand Pharma A/S stock?

ZEAL stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE.

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $13.75.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S (NASDAQ:ZEAL) has a market capitalization of $639.79 million and generates $46.54 million in revenue each year. The company earns $-161.99 million in net income (profit) each year or ($3.62) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 355 workers across the globe.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The official website for Zealand Pharma A/S is www.zealandpharma.com. The company can be reached via phone at (458) 877-3600, via email at [email protected], or via fax at 45-8877-3898.

This page (NASDAQ:ZEAL) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.